



Published on *Drug Pipeline* (<https://www.drugpipeline.net>)

Home > Migraine - Market Insights, Epidemiology and Market Forecast-2027

Migraine - Market Insights, Epidemiology and Market Forecast-2027

Publication ID:

DEL0818008

Publication Date:

August 03, 2018

Pages:

120

Publisher:

Delveinsight

Region:

Global [1]

\$6,250.00

Publication License Type *

Single User License (PDF), \$6,250.00

Site License (PDF), \$12,500.00

Global License (PDF), \$18,750.00

Please choose the suitable license type from above. More details are at given under tab "Report License Types" below.

Add to cart



Description:

DelveInsight's 'Migraine - Market Insights, Epidemiology and Market Forecast-2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Migraine in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Migraine from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

- The United States
- EU5 (Germany, France, Italy, Spain and the United Kingdom)
- Japan

Study Period: 2016-2027

Migraine - Disease Understanding and Treatment Algorithm

Migraine is an inherited tendency to have headaches with sensory disturbance. It's an instability in the way the brain deals with incoming sensory information, and that instability can become influenced by physiological changes like sleep, exercise and hunger. It is one of the most common and most prevalent neurological disease with extremely incapacitating neurological symptoms. It includes severe throbbing recurring pain, usually on one side of the head, often accompanied by visual disturbances, nausea, vomiting, dizziness, extreme sensitivity to sound, light, touch and smell, and tingling or numbness in the extremities or face.

The DelveInsight Migraine market report gives the thorough understanding of the Migraine by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Migraine in the US, Europe, and Japan.

Migraine Epidemiology

The Migraine epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology [segmented as Prevalent Cases, Type Specific Prevalence (Acute, Chronic and Episodic), and Diagnosed and Treatable Population] scenario of Migraine in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to the US Centers for Disease Control, self-reported migraine prevalence in the United

States increased by 60%, from 25.8 to 41 per 1000 person-years between 1981 and 1989. The World Health Organization's disability rating for migraine, ranks it as the 19th most common reason for disability.

Migraine Drug Chapters

This segment of the Migraine report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

On the basis of treatment type, the Migraine drugs market is broadly classified into two types of therapies: pain-relieving and preventive. Recently in May 2018, U.S. FDA approved a new drug, Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine.

Migraine Market Outlook

The Migraine market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key players such as IMPAX Laboratories, Inc., Zosano Pharma Corporation, Biohaven Pharmaceuticals, Inc., Allergan and many others are involved in developing therapies for Migraine. Expected launch of emerging therapies such as IPX229 (IMPAX Laboratories, Inc.) and M207/ADAM Zolmitriptan (Zosano Pharma Corporation), Rimegepant (Biohaven Pharmaceuticals, Inc.), Ubrogapant (Allergan) etc. are expected to create a noticeable increase in the market size of Migraine in the upcoming years.

Migraine Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2016-2027. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Migraine Report Insights

- Patient Population
- Therapeutic Approaches
- Pipeline Analysis
- Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies

Migraine Report Key Strengths

- 10 Years Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Sub-type Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake

Migraine Report Assessment

- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers

Key Benefits

- This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Migraine market
- Organize sales and marketing efforts by identifying the best opportunities for Migraine market
- To understand the future market competition in the Migraine market.

Please Note - This report will available in 7-10 Business Days after purchase.

Table Of Contents:

1. Report Introduction
2. Migraine Market Overview at a Glance
 - 2.1. 7 Major Market Size of Migraine in 2017
 - 2.2. 7 Major Market Size of Migraine in 2027
3. Disease Background and Overview: Migraine
 - 3.1. Introduction
 - 3.2. Causes
 - 3.3. Pathophysiology
 - 3.4. Symptoms
 - 3.5. Risk Factor
 - 3.6. Diagnosis

4. Epidemiology and Patient Population

4.1. Assumptions and Caveats

4.2. 7MM Prevalent cases of Migraine (2016-2027)

4.3. Type specific prevalent cases of Migraine in 7MM (2016-2027)

4.4. Diagnosed and Treatable cases of Migraine in 7MM (2016-2027)

5. Migraine: Country-Wise Epidemiology

5.1. United States

5.1.1. Prevalent cases of Migraine in the US (2016-2027)

5.1.2. Type specific prevalent cases of Migraine in the US (2016-2027)

5.1.3. Diagnosed and Treatable cases of Migraine in the US (2016-2027)

5.2. EU-5

5.2.1. Germany

5.2.1.1. Prevalent cases of Migraine in Germany (2016-2027)

5.2.1.2. Type specific prevalent cases of Migraine in Germany (2016-2027)

5.2.1.3. Diagnosed and Treatable cases of Migraine in Germany (2016-2027)

5.2.2. France

5.2.2.1. Prevalent cases of Migraine in the France (2016-2027)

5.2.2.2. Type specific prevalent cases of Migraine in France (2016-2027)

5.2.2.3. Diagnosed and Treatable cases of Migraine in France (2016-2027)

5.2.3. Italy

5.2.3.1. Prevalent cases of Migraine in Italy (2016-2027)

5.2.3.2. Type specific prevalent cases of Migraine in Italy (2016-2027)

5.2.3.3. Diagnosed and Treatable cases of Migraine in Italy (2016-2027)

5.2.4. Spain

5.2.4.1. Prevalent cases of Migraine in Spain (2016-2027)

5.2.4.2. Type specific prevalent cases of Migraine in Spain (2016-2027)

5.2.4.3. Diagnosed and Treatable cases of Migraine in Spain (2016-2027)

5.2.5. United Kingdom

5.2.5.1. Prevalent cases of Migraine in the UK (2016-2027)

5.2.5.2. Type specific prevalent cases of Migraine in the UK (2016-2027)

5.2.5.3. Diagnosed and Treatable cases of Migraine in the UK (2016-2027)

5.3. Japan

5.3.1. Prevalent cases of Migraine in Japan 2016-2027)

5.3.2. Type specific prevalent cases of Migraine in Japan (2016-2027)

5.3.3. Diagnosed and Treatable cases of Migraine in Japan (2016-2027)

6. Treatment & Medical Practices

6.1. Treatment Algorithm

6.2. Treatment Guidelines

7. Marketed Drugs

7.1. Aimvoig (erenumab)- Amgen and Novartis

- 7.1.1. Product Description
- 7.1.2. Mechanism of action
- 7.1.3. Regulatory milestones
- 7.1.4. Other Development Activities
- 7.1.5. Safety and Efficacy
- 7.1.6. Advantages and Disadvantages
- 7.1.7. Product Profile

7.2. RELPAX (eletriptan hydrobromide)- Pfizer

- 7.2.1. Product Description
- 7.2.2. Mechanism of action
- 7.2.3. Regulatory milestones
- 7.2.4. Other Development Activities
- 7.2.5. Safety and Efficacy
- 7.2.6. Advantages and Disadvantages
- 7.2.7. Product Profile

List to be continued in the report...

8. Emerging Therapies

- 8.1. Key Cross Competition
- 8.2. Galcanezumab- Eli Lilly
 - 8.2.1. Regulatory Milestones
 - 8.2.2. Clinical Development
 - 8.2.3. Product Profile
 - 8.2.4. Clinical Pipeline Activity
 - 8.2.4.1. Ongoing Trials Information
 - 8.2.4.2. Clinical Trial by Phase
- 8.3. ADAM Zolmitriptan- Zosan Pharmaceuticals
 - 8.3.1. Regulatory Milestones
 - 8.3.2. Clinical Development
 - 8.3.3. Product Profile
 - 8.3.4. Clinical Pipeline Activity
 - 8.3.4.1. Ongoing Trials Information
- 8.4. Rimegepant- Biohaven Pharmaceuticals
 - 8.4.1. Regulatory Milestones
 - 8.4.2. Clinical Development
 - 8.4.3. Product Profile
 - 8.4.4. Clinical Pipeline Activity
- 8.5.5.1 Ongoing Trials Information
- 8.5. Ubrogepant- Allergan
 - 8.5.1. Regulatory Milestone
 - 8.5.2. Clinical Development

- 8.5.3. Product Pipeline
- 8.5.4. Clinical Pipeline Activity
- 8.6.6.1 Ongoing Trial Information
- List to be continued in the report...
- 9. 7MM Migraine: Country-Wise Market Analysis
 - 9.1. United States
 - 9.1.1. Total Market Size of Migraine
 - 9.1.2. Market Size of Migraine by Therapies
 - 9.2. Germany
 - 9.2.1. Total Market Size of Migraine
 - 9.2.2. Market Size of Migraine by Therapies
 - 9.3. France
 - 9.3.1. Total Market Size of Migraine
 - 9.3.2. Market Size of Migraine by Therapies
 - 9.4. United Kingdom
 - 9.4.1. Total Market Size of Migraine
 - 9.4.2. Market Size of Migraine by Therapies
 - 9.5. Spain
 - 9.5.1. Total Market Size of Migraine
 - 9.5.2. Market Size of Migraine by Therapies
 - 9.6. Italy
 - 9.6.1. Total Market Size of Migraine
 - 9.6.2. Market Size of Migraine by Therapies
 - 9.7. Japan
 - 9.7.1. Total Market Size of Migraine
 - 9.7.2. Market Size of Migraine by Therapies
- 10. Report Methodology
 - 10.1. Sources Used
- 11. DelveInsight Capabilities
- 12. Disclaimer
- 13. About DelveInsight

List of Tables

- Table 1 7MM Prevalent cases of Migraine (2016-2027)
- Table 2 7MM Type specific prevalent cases of Migraine (2016-2027)
- Table 3 7MM Diagnosed and Treatable cases of Migraine (2016-2027)
- Table 4 Prevalent cases of Migraine in the US (2016-2027)
- Table 5 Type specific prevalent cases of Migraine in the US (2016-2027)
- Table 6 Diagnosed and Treatable cases of Migraine in the US (2016-2027)
- Table 7 Prevalent cases of Migraine in Germany (2016-2027)

Table 8 Type specific prevalent cases of Migraine in Germany (2016-2027)

Table 9 Diagnosed and Treatable cases of Migraine in Germany (2016-2027)

Table 10 Prevalent cases of Migraine in France (2016-2027)

Table 11 Type specific prevalent cases of Migraine in France (2016-2027)

Table 12 Diagnosed and Treatable cases of Migraine in France (2016-2027)

Table 13 Prevalent cases of Migraine in Italy (2016-2027)

Table 14 Type specific prevalent cases of Migraine in Italy (2016-2027)

Table 15 Diagnosed and Treatable cases of Migraine in Italy (2016-2027)

Table 16 Prevalent cases of Migraine in Spain (2016-2027)

Table 17 Type specific prevalent cases of Migraine in Spain (2016-2027)

Table 18 Diagnosed and Treatable cases of Migraine in Spain (2016-2027)

Table 19 Prevalent cases of Migraine in the UK (2016-2027)

Table 20 Type specific prevalent cases of Migraine in the UK (2016-2027)

Table 21 Diagnosed and Treatable cases of Migraine in the UK (2016-2027)

Table 22 Prevalent cases of Migraine in Japan (2016-2027)

Table 23 Type specific prevalent cases of Migraine in Japan (2016-2027)

Table 24 Diagnosed and Treatable cases of Migraine in Japan (2016-2027)

Table 25 ADAM Zolmitriptan, Clinical Trials by Recruitment status, 2018

Table 26 ADAM Zolmitriptan, Clinical Trials by Zone, 2018

Table 27 Rimegepant, Clinical Trials by Recruitment status, 2018

Table 28 Rimegepant, Clinical Trials by Zone, 2018

Table 29 Ubrogapant, Clinical Trials by Recruitment status, 2018

Table 30 Ubrogapant, Clinical Trials by Zone, 2018

Table 31 7 Major Market Size of Migraine in USD, Million (2016-2027)

Table 32 Region wise Market Size of Migraine in USD, Million (2016-2027)

Table 33 7MM-Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 34 United States Market Size of Migraine in USD, Million (2016-2027)

Table 35 United States Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 36 Germany Market Size of Migraine in USD, Million (2016-2027)

Table 37 Germany Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 38 France Market Size of Migraine in USD, Million (2016-2027)

Table 39 France Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 40 Italy Market Size of Migraine in USD, Million (2016-2027)

Table 41 Italy Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 42 Spain Market Size of Migraine in USD, Million (2016-2027)

Table 43 Spain Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 44 United Kingdom Market Size of Migraine in USD, Million (2016-2027)

Table 45 United Kingdom Market Size of Migraine by Therapy in USD, Million (2016-2027)

Table 46 Japan Market Size of Migraine in USD, Million (2016-2027)

Table 47 Japan Market Size of Migraine by Therapy in USD, Million (2016-2027)

List of Figures

- Figure 1 7MM Prevalent cases of Migraine (2016-2027)
- Figure 2 7MM Type specific prevalent cases of Migraine (2016-2027)
- Figure 3 7MM Diagnosed and Treatable cases of Migraine (2016-2027)
- Figure 4 Prevalent cases of Migraine in the US (2016-2027)
- Figure 5 Type specific prevalent cases of Migraine in the US (2016-2027)
- Figure 6 Diagnosed and Treatable cases of Migraine in the US (2016-2027)
- Figure 7 Prevalent cases of Migraine in Germany (2016-2027)
- Figure 8 Type specific prevalent cases of Migraine in Germany (2016-2027)
- Figure 9 Diagnosed and Treatable cases of Migraine in Germany (2016-2027)
- Figure 10 Prevalent cases of Migraine in France (2016-2027)
- Figure 11 Type specific prevalent cases of Migraine in France (2016-2027)
- Figure 12 Diagnosed and Treatable cases of Migraine in France (2016-2027)
- Figure 13 Prevalent cases of Migraine in Italy (2016-2027)
- Figure 14 Type specific prevalent cases of Migraine in Italy (2016-2027)
- Figure 15 Diagnosed and Treatable cases of Migraine in Italy (2016-2027)
- Figure 16 Prevalent cases of Migraine in Spain (2016-2027)
- Figure 17 Type specific prevalent cases of Migraine in Spain (2016-2027)
- Figure 18 Diagnosed and Treatable cases of Migraine in Spain (2016-2027)
- Figure 19 Prevalent cases of Migraine in the UK (2016-2027)
- Figure 20 Type specific prevalent cases of Migraine in the UK (2016-2027)
- Figure 21 Diagnosed and Treatable cases of Migraine in the UK (2016-2027)
- Figure 22 Prevalent cases of Migraine in Japan (2016-2027)
- Figure 23 Type specific prevalent cases of Migraine in Japan (2016-2027)
- Figure 24 Diagnosed and Treatable cases of Migraine in Japan (2016-2027)
- Figure 25 ADAM Zolmitriptan, Clinical Trials by Recruitment status, 2018
- Figure 26 ADAM Zolmitriptan, Clinical Trials by Zone, 2018
- Figure 27 Rimegepant, Clinical Trials by Recruitment status, 2018
- Figure 28 Rimegepant, Clinical Trials by Zone, 2018
- Figure 29 Ubrogapant, Clinical Trials by Recruitment status, 2018
- Figure 30 Ubrogapant, Clinical Trials by Zone, 2018
- Figure 31 7 Major Market Size of Migraine in USD, Million (2016-2027)
- Figure 32 Region wise Market Size of Migraine in USD, Million (2016-2027)
- Figure 33 7MM-Market Size of Migraine by Therapy in USD, Million (2016-2027)
- Figure 34 United States Market Size of Migraine in USD, Million (2016-2027)
- Figure 35 United States Market Size of Migraine by Therapy in USD, Million (2016-2027)
- Figure 36 Germany Market Size of Migraine in USD, Million (2016-2027)
- Figure 37 Germany Market Size of Migraine by Therapy in USD, Million (2016-2027)
- Figure 38 France Market Size of Migraine in USD, Million (2016-2027)
- Figure 39 France Market Size of Migraine by Therapy in USD, Million (2016-2027)

Figure 40 Italy Market Size of Migraine in USD, Million (2016-2027)

Figure 41 Italy Market Size of Migraine by Therapy in USD, Million (2016-2027)

Figure 42 Spain Market Size of Migraine in USD, Million (2016-2027)

Figure 43 Spain Market Size of Migraine by Therapy in USD, Million (2016-2027)

Figure 44 United Kingdom Market Size of Migraine in USD, Million (2016-2027)

Figure 45 United Kingdom Market Size of Migraine by Therapy in USD, Million (2016-2027)

Figure 46 Japan Market Size of Migraine in USD, Million (2016-2027)

Figure 47 Japan Market Size of Migraine by Therapy in USD, Million (2016-2027)

Figure 48 Market Drivers

Figure 49 Market Barriers

License Types:

Single User License (PDF)

- This license allows for use of a publication by one person.
- This person may print out a single copy of the publication.
- This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- This person cannot share the publication (or any information contained therein) with any other person or persons.
- Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Site License (PDF)*

- This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
- These users may print out a single copy of the publication.
- These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
- These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
- Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
- Customers who infringe these license terms are liable for a Global license fee.

Global License (PDF)*

- This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
- Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
- These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.



No. 1101, Golden Square, 3rd Floor,
24th Main, J P Nagar, 1st Phase,
Bangalore, Karnataka, India- 560078

India: +91-8762746600

info@domain.com

-->

NAVIGATE

[About Us](#)

[Reports by Region](#)

[FAQ](#)

[Privacy Policy](#)

[TERMS & CONDITIONS](#)

[CONTACT](#)

RECENT POSTS

What is drug pipeline research?

March 20

How to use market research to bring your idea to life?

March 11

How to gain business insights using syndicated market research?

March 10

Source URL: <https://www.drugpipeline.net/delveinsight/migraine-market-insights-epidemiology-and-market-forecast-2027>

Links

[1] <https://www.drugpipeline.net/region/global>